Zinger Key Points
- Tavapadon 5 mg and 15 mg doses showed significant reductions in MDS-UPDRS scores at week 26, compared to placebo.
- AbbVie plans to present the full results at medical conferences and expects additional trial data from TEMPO-2 by the end of 2024.
- Get New Picks of the Market's Top Stocks
On Thursday, AbbVie Inc ABBV released topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson’s disease.
Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson’s disease. AbbVie added the drug candidate with its $8.7 billion buyout of Cerevel Therapeutics.
The TEMPO-1 trial evaluated the efficacy, safety and tolerability of two fixed doses (5 mg and 15 mg, once daily) of tavapadon as a monotherapy in adults with early Parkinson’s disease.
Also Read: UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars.
The trial met its primary endpoint – patients treated with tavapadon in both dose groups experienced a statistically significant reduction (improvement) from baseline compared to placebo (placebo: +1.8; 5 mg: -9.7; 15 mg: -10.2 versus placebo) in the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II and III combined score at week 26.
MDS-UPDRS assesses motor and non-motor symptoms of Parkinson’s disease.
The TEMPO-1 trial also met the key secondary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor aspects of experiences of daily living (MDS-UPDRS Part II) in both tavapadon dose groups compared to placebo at week 26.
The safety profile observed in the TEMPO-1 trial was consistent with prior clinical trials. The majority of adverse events reported were mild to moderate in severity.
Full results from the TEMPO-1 study will be submitted for presentation at future medical meetings and used to support regulatory submissions of tavapadon as a treatment for Parkinson’s disease.
Topline results from TEMPO-2, the Phase 3 flexible-dose monotherapy trial for tavapadon, are expected by the end of 2024.
Price Action: ABBV stock is up 0.33% at $191.90 at the last check on Wednesday.
Read Next:
Photo via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
